FDA to Convene Expert Panel on Expanding Access to Peptides Amid Safety, Regulatory Debate

The FDA will convene an expert advisory panel in July 2026 to evaluate whether certain peptides should become more widely accessible through licensed compounding pharmacies, signaling a potential shift in regulatory oversight amid growing demand and ongoing safety concerns.¹

This advisory committee will meet on July 23 and 24 to review evidence on a group of peptides previously restricted due to concerns about immunogenicity, toxicity, impurities, and insufficient human data, according to Reuters. These restrictions, implemented in 2023, affected at least 14 peptides that had gained popularity in wellness, fitness, and integrative medicine communities despite limited clinical validation.

The upcoming review will include peptides such as BPC-157, TB-500, and MOTS-c, which are often marketed for applications ranging from injury recovery to inflammation reduction and weight management. The panel’s recommendations could influence whether compounding pharmacies are permitted to produce a broader range of these substances under physician oversight.

The policy discussion comes amid increasing public and political interest in peptides, including support from federal health leadership for expanding access through regulated channels. Proponents argue that allowing compounding pharmacies to produce peptides could reduce reliance on unregulated or overseas sources, potentially improving patient safety. However, critics warn that expanding access without robust clinical evidence may expose patients to unknown risks and blur the line between dietary supplements and pharmaceutical therapies.

In a recent FAQ article with The American Journal of Managed Care^® (AJMC^®), Christopher Shade, PhD, founder and CEO of Quicksilver Scientific, highlighted the scientific challenges underlying peptide use, particularly for oral formulations.² Peptides are inherently difficult to deliver effectively due to degradation in the gastrointestinal tract and limited absorption across intestinal membranes, resulting in low systemic bioavailability. These pharmacokinetic barriers complicate both clinical development and real-world use, reinforcing concerns about inconsistent efficacy and dosing.

“You have 2 problems,” explained Shade in an interview with AJMC. “One is peptides are small amino acid chains, proteins are just big amino acid chains, and your digestive system is designed to break down proteins into amino acids, so it breaks down peptides too. Your first challenge is not breaking the peptide down, but then the second challenge is, how does it get absorbed?”

At the same time, advances in peptide engineering and delivery systems are driving renewed interest in their therapeutic potential. Oral peptide therapies, if successfully developed, could improve patient adherence compared with injectable alternatives, but significant technical hurdles remain before widespread clinical adoption is feasible.

For managed care stakeholders, the FDA’s pending decision raises important questions about coverage, utilization management, and evidence standards. Broader access to compounded peptides could increase demand for therapies that lack rigorous clinical trial data, potentially complicating formulary decisions and reimbursement policies.

The outcome of the July advisory meeting may ultimately shape the regulatory pathway for peptides in the US, balancing patient access with safety and evidence requirements. As interest in these therapies continues to grow, the FDA’s approach could set a precedent for how emerging, nontraditional treatments are evaluated and integrated into clinical care.

“As long as they are natural peptides, not engineered, and they're not drugs, and they could be found in a gland, we'll promote those as dietary supplements,” said Shade. “We've talked to some of the people in the administration over at HHS, and they were very on board with how we do it. Kennedy [HHS Secretary Robert F. Kennedy Jr] is about to release a list of peptides that were on the ‘do not compound’ list, and he's going to release them off of there so they can be compounded again.”

References

1. Choudhury K, K S. US FDA to convene expert panel to review wider access to some peptides. Reuters. April 15, 2026. Accessed April 16, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-convene-expert-panel-decide-broader-access-some-peptides-2026-04-15/

2. Steinzor P. Oral peptides: FAQs on bioavailability, safety, and clinical use. AJMC. March 25, 2026. Accessed April 16, 2026. https://www.ajmc.com/view/oral-peptides-faqs-on-bioavailability-safety-and-clinical-use